Prognose

Vi har ingen analytikerdata for denne virksomhed.

Nyheder Til nyhedsfeedet

Nanobiotix completes capital increase of around 100 million US dollars

Nanobiotix placed 2,218,467 common shares (including ADS) plus 345,099 pre-funded warrants following full exercise of the overallotment option and raised gross proceeds of about 100 million US dollars. The subscription price was €33.60 per common share ($38.98 per ADS) and represented a 14.92% discount to the volume-weighted average price. Net proceeds are intended to finance <10% the development of JNJ-1900 (NBTXR3), 50–60% the Nanoprimer and other platforms, and 30–40% general corporate purposes; the company expects that, together with existing cash, this will cover funding needs through 2029. Given a current market capitalization of $16.67 million, the transaction leads to significant dilution for existing shareholders. » Mere på de.investing.com
Nanobiotix share rises after positive Jefferies analysis and price target increase

Jefferies raised its price target for Nanobiotix from €21.50 to €60.00, citing reduced risks following positive study data for NBTXR3 in non‑small cell lung cancer. The stock climbed intraday by as much as 11.58% to €37.40, thereby holding its 21‑day moving average after a recent pullback. Analyst Shan Hama also praised a capital increase that secures the company’s financing through 2029. » Mere på finanzen.net
FDA approves protocol amendment for Nanobiotix study in head and neck cancer

The FDA has approved a protocol amendment for the global Phase 3 study NANORAY-312, submitted by sponsor Johnson & Johnson, which removes a planned interim analysis. The final analysis will be adjusted to require fewer events; the readout is expected to occur in a similar timeframe as the originally planned interim analysis. The agent JNJ-1900 (NBTXR3) will continue to be evaluated in locally advanced squamous cell carcinomas of the head and neck; under its license agreement with Janssen, Nanobiotix may be eligible for future milestone payments. » Mere på de.investing.com

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 2022 har Nanobiotix allerede udloddet 0,26 € i udbytte. Den seneste udlodning fandt sted i marts 2022.

Virksomhedstal

I det seneste kvartal havde Nanobiotix en omsætning på 3,01 mio. € og et nettoresultat på -18,58 mio. €

(EUR)	december 2025	YoY
Omsætning	3,01 mio.	-
Bruttofortjeneste	3,01 mio.	-
Nettoresultat	-18,58 mio.	-
EBITDA	-13,16 mio.	-

Fundamentale data

Nøgletal	Værdi
Markedsværdi	1,58 mia. €
Antal aktier	50,8 mio.
Højeste/laveste i 52 uger	47,66 € - 7,92 €
Udbytte	Nej
Beta	0,57
P/E (PE Ratio)	-61,02
PEG (PEG Ratio)	-0,67
K/I (PB Ratio)	-17,47
P/S (PS Ratio)	53,33

Virksomhedsprofil

Nanobiotix S.A., ein Biotechnologieunternehmen in der klinischen Phase, konzentriert sich auf die Entwicklung von Produktkandidaten für die Behandlung von Krebs. Der führende Produktkandidat ist NBTXR3, eine sterile wässrige Suspension von kristallinen Hafniumoxid-Nanopartikeln, die zur Behandlung von Weichteilsarkomen, Kopf- und Halskrebs, Leberkrebs, Prostatakrebs, Bauchspeicheldrüsenkrebs, Speiseröhrenkrebs, Rektumkrebs und nicht-kleinzelligem Lungenkrebs eingesetzt wird. Nanobiotix S.A. hat eine Partnerschaft mit LianBio zur Entwicklung und Vermarktung von NBTXR3 im Großraum China, Südkorea, Singapur und Thailand. Das Unternehmen wurde im Jahr 2003 gegründet und hat seinen Hauptsitz in Paris, Frankreich.